Table 4.
Effectiveness of Pneumococcal Conjugate Vaccine Doses Among Children Aged ≥13 Months
| Age, Months | Vaccine Exposure | Carriage Endpoint | Dosing Comparisons | ||||
|---|---|---|---|---|---|---|---|
| 2p+1b ref. 0p+0b | 2p+0b ref. 2p+1b | 1p+1b ref. 2p+1b | 0p+2b ref. 2p+1b | ||||
| mOR (95% CI) | VE (95% CI), % | mOR (95% CI) | mOR (95% CI) | mOR (95% CI) | |||
| 13–24 | PCV7/13 doses | PCV7 serotypes | .38 (.25–.56) | 62 (44–75) | 2.83 (1.87–4.34) | 1.94 (1.06–4.40) | 1.05 (.48–2.28) |
| PCV13 doses only | All PCV13 serotypes | .60 (.33–.96) | 40 (4–67) | 3.33 (2.28–3.93) | 2.05 (1.12–5.00) | 4.60 (2.34–6.00) | |
| +6PCV13 serotypes | … | … | 3.73 (2.58–6.12) | … | … | ||
| PCV7 serotypes | .29 (.17–.50) | 71 (50–83) | 3.16 (1.94–5.31) | 2.96 (1.67–5.00) | … | ||
| PCV7 doses only | PCV7 serotypes | … | … | 1.17 (.89–1.77) | 1.48 (.73–3.31) | 1.29 (.63–1.28) | |
| 25–59 | PCV7/13 doses | PCV7 serotypes | .36 (.16–1.91) | 64 (−91–84) | 1.79 (1.01–3.65) | 1.68 (1.00–3.00) | … |
| PCV13 doses only | All PCV13 serotypes | .38 (.17–.67) | 62 (33–83) | 0.95 (.53–2.09) | … | … | |
| +6PCV13 serotypes | … | … | 1.99 (1.00–6.00) | … | … | ||
| PCV7 serotypes | … | … | 1.13 (.76–2.34) | … | … | ||
| PCV7 doses only | PCV7 serotypes | .37 (.25–.41) | 63 (59–75) | 1.39 (1.00–3.00) | … | … |
Vaccine effectiveness estimates are calculated as 1-mOR times 100%. Matched odds ratios are calculated from the relative odds of receipt of each vaccination series among case children versus matched controls. Comparisons are structured as “2p + 1b ref. 0p + 0b”, “2p + 0b ref. 2p + 1b”, etc., to present the effectiveness of alternative vaccination schedules. Here, “2p + 1b ref 0p + 0b” presents the effectiveness of 2p + 1b dosing, compared to receipt of zero primary series or booster doses. “2p + 0b ref. 2p + 1b” presents the effectiveness of 2p + 0b dosing, compared to receipt of the standard 2p + 1b schedule.
Abbreviations: +6PCV13, the 6 serotypes contained in PCV13 and not PCV7; b, booster dose; CI, confidence interval; mOR, matched odds ratio; OR, odds ratio; p, primary dose; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; VE, vaccine effectiveness.